Agios Pharmaceuticals AGIO Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Agios Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The official record: Agios Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Agios Pharmaceuticals's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Agios Pharmaceuticals's retained earnings?
- Agios Pharmaceuticals (AGIO) reported retained earnings of -$660.82M in Q1 2026.
- How has Agios Pharmaceuticals's retained earnings changed year-over-year?
- Agios Pharmaceuticals's retained earnings decreased by 177.4% year-over-year, from -$238.21M to -$660.82M.
- What is the long-term trend for Agios Pharmaceuticals's retained earnings?
- Over 5 years (2020 to 2025), Agios Pharmaceuticals's retained earnings has grown at a -21.2% compound annual growth rate (CAGR), from -$1.84B to -$561.71M.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.